ondansetron
CLINICAL USE
Anti-emetic
DOSE IN NORMAL RENAL FUNCTION
Oral: 4–24 mg daily in 2–3 divided dosesIV: 8–32 mg dailyPR: 16 mg pre-chemotherapy
PHARMACOKINETICS
Molecular weight                           :293.4 %Protein binding                           :70–76 %Excreted unchanged in urine     : <5 Volume of distribution (L/kg)       :2half-life – normal/ESRD (hrs)      :3–6/5.4 DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50     : Dose as in normal renal function 10 to 20     : Dose as in normal renal function <10           : Dose as in normal renal function DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Unlikely to be dialysed. Dose as in normal renal function HD                     :Not dialysed. Dose as in normal renal functionHDF/high flux   :Unknown dialysability. Dose as in normal renal function CAV/VVHD      :Unknown dialysability. Dose as in normal renal function IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugsNone known ADMINISTRATION
Reconstition
– Route
Oral, IV, IM, rectal Rate of Administration
IV bolus over 3–5 minutes IV infusion
: over 15 minutes Continuous infusion: 1 mg/hour Comments
Dilute in 50–100 mL of sodium chloride 0.9% or glucose 5% OTHER INFORMATION
Can be used to treat uraemic pruritus Renal clearance of ondansetron is low
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home